Overall, our study confirmed a differential BCR‐free survival for ERG tumor groups, defined as ERGhigh and ERGlow, in Hispanic/Latino patients with localized/regionally advanced PCa, with ERGlow tumor cases having the worst survival. The gene discussed is BCR; the disease is neoplasm.